This database includes MPT products that are currently available, as well as MPT products in active development. The database outlines detailed product information and can be searched to display products by desired criteria as selected from the drop-down boxes or by entering a keyword in the search box. Click on the product name to access detailed information on each product. Please note there are other MPT candidates not listed that may move forward pending funding. Click here to learn more about the inclusion criteria and information update methodology.
Know of an MPT product not included in this database or have updated information for listed products? Let us know here!
Click on the table for MPT products in the development pipeline by indication combination.
Novel mAb contraceptive + TDF IVR
MPT in Development
Development Stage:
Preclinical – Early (Pre1)
Hormonal/Non-Hormonal:
NonHormonal
Delivery Route & Method:
Topical -
Intravaginal Ring (IVR)
Mechanism of Action:
Nucleoside analogue reverse transcriptase inhibitor (NRTI) and sperm agglutinating antibody
Developer:
Oak Crest Institute of Science
University of North Carolina, Chapel Hill
Funding:
Nat. Institute Child Health & Human Development (NICHD)
Funding Mechanism:
NICHD: R01
Active Ingredient:
Monoclonal Antibodies
Tenofovir Disoproxil Fumarate (TDF)
Product Indications:
HIV
Pregnancy
Description: Formulation of a novel, nonhormonal contraceptive agent based on a multivalent monoclonal antibody (mAb) that blocks sperm from swimming through mucus and accessing the egg with antiretroviral (ARV) agents with demonstrated clinical efficacy in preventing HIV in a behavior-monitoring IVR.
